On our screens:Cheap stocks by free cash flow yield
The financials
Viatris by the numbers
Viatris (VTRS) reported revenue of $3.76B in Q2 2026 (quarter ended Jun 30, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 39% and net loss of $119M. For the full year FY2025, revenue was $14.3B (−3.0% year on year) and net income −$3.51B. Its largest product in Q2 2026 was Brands at $1.12B, 30% of the disclosed total, just ahead of Generics at 29%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.76B | $3.58B | +4.9% |
| Gross profit | $1.46B | $1.33B | +9.3% |
| Operating income | $6.3M | $233M | −97% |
| Net income | −$119M | −$4.6M | n/a |
| Diluted EPS | −$0.10 | $0.00 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Brands | $1.12B | 30% |
| Generics | $1.07B | 29% |
| Lipitor | $452M | 12% |
| Norvasc | $200M | 5.3% |
| Epi Pen Auto Injectors | $129M | 3.4% |
| Lyrica | $121M | 3.2% |
| Viagra | $113M | 3.0% |
| Creon | $97M | 2.6% |
| Celebrex | $76M | 2.0% |
| Zoloft | $71M | 1.9% |
| Yupelri | $71M | 1.9% |
| Effexor | $67M | 1.8% |
| Dymista | $40M | 1.1% |
| Amitiza | $39M | 1.1% |
| Xalabrands | $39M | 1.0% |
| Xanax | $38M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $3.75B (+6.6%)
Zoloft grew +17% year on yearDymista -18% year on year
Segment Latestquarter on quarteryear on year
- Brands$1.12B$1.12BQoQ +5.0%year on year +0.08%+5.0%+0.08%
- Generics$1.07B$1.07BQoQ +13%year on year +7.4%+13%+7.4%
- Lipitor$452.2M$452.2MQoQ -2.1%year on year +17%-2.1%+17%
- Norvasc$200.2M$200.2MQoQ -4.7%year on year +9.6%-4.7%+9.6%
- Epi Pen Auto Injectors$129.2M$129.2MQoQ +28%year on year -5.6%+28%-5.6%
- Lyrica$120.6M$120.6MQoQ 0.00%year on year -5.9%0.00%-5.9%
- Viagra$112.9M$112.9MQoQ +19%year on year +13%+19%+13%
- Creon$97.4M$97.4MQoQ 0.00%year on year +6.6%0.00%+6.6%
- Celebrex$76.4M$76.4MQoQ +14%year on year +9.1%+14%+9.1%
- Zoloft$71.4M$71.4MQoQ -1.7%year on year +17%-1.7%+17%
- Yupelri$70.7M$70.7MQoQ +13%year on year +6.2%+13%+6.2%
- Effexor$66.7M$66.7MQoQ +7.6%year on year +5.7%+7.6%+5.7%
- Dymista$39.8M$39.8MQoQ +6.7%year on year -18%+6.7%-18%
- Amitiza$39.4M$39.4MQoQ +16%year on year -5.3%+16%-5.3%
- Xalabrands$38.8M$38.8MQoQ -1.0%year on year -4.7%-1.0%-4.7%
- Xanax$38.1M$38.1MQoQ +9.5%year on year +12%+9.5%+12%
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry